1Zoulim F. Mechanism of viral persistence and resistance to nueleoside and nucleotide analogs in chronic hepatitis B virus infection.Antiviral Res,200d.,64:1 - 15
2Feld J, Locamini S. Antiviral therapy for hepatitis B virus infections:new targets and technical challenges. J Clinical Virol, 2002,25 : 267 - 283
3Akuta N, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol, 2003,38 : 315 - 321
4Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 2002,347 : 168 - 174
5Lok ASF, Me Mahon BJ. Chronic hepatitis B: Update of recommendations. Hepatology, 2004,39 : 857 - 861
6The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003,38 : 533 - 540
1Core Working Party for the Asia-Pacific consensus on hepatitis B,C.Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region.Gastroenterol Hepatol,2000,15(8):825-841
3Liaw YF,Tasi SL.Pathogenesis and clinical significance of acute exacerbation and remissions in patients with chronic hepatitis B virus infection.Viral Hep Rev,1997,3(1):143-154
4Hsu YS,Chien RN,Yeh CT,et al.Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.Hepatology,2002,35(6):1522-1527
5Kao JH.Hepatitis B viral genotypes:clinical relevance and molecular characteristics.Gastroenterol Hepatol,2002,17(4):643-650
6Lai MY,Cooksley WGE,Piravisuth T et al.Efficacy and safety of peginterferon alfa-2A(40KD)(PEGASYS)in HBeAg-positive chronic hepatitis B(CHB):48-week results from a phase Ⅱstudy.Gastroenterol Hepatol,2002,17(Suppl):A27
7Leung N.Nucleoside analogues in the treatment of chronic hepatitis B.Gastroenterol Hepatol,2000,15(suppl):E53-E60
8Chien RN,Liaw YF,Atkins M.Pretherapy alanine transaminase level as a determinant for hepatitis B antiger seroconversion during lamivudine therapy in patients with chronic hepatitis B.Hepatology,1999,30(3):770-774
9Guan R,Lai CL,Liaw YF,et al.Efficacy and safety of 5 years' lamivudine treatment of Chinese patients with chronic hepatitis B.F Gastroenterol Hepatol,2001,16(Suppl):A60
10Rossi G,Pelizzari A,Motta M,et al,Primary prophylaxi with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy.Br Haematol,2001,115(1):58-62
